Innovation competition is not a speculative theory of harm, Csiszár says
Contractual terms in deals between drugmakers show that mergers can change companies’ incentives to innovate, a senior EU competition official has said.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.